Publications
Selected Publications
1. Hsu J.+,
Hodgins J.J.+, Marathe M., Nicolai C.J., Bourgeois-Daigneault M.C., Trevino
T.N., Azimi C.S., Scheer A.K., Randolph H.E., Thompson T.W., Zhang L., Iannello
A., Mathur N., Jardine K.E., Kirn G.A., Bell J.C., McBurney M.W., Raulet D.H. and Ardolino M. Contribution
of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade.
The Journal of Clinical Investigation, 2018, 128(10):4654-4688
2. Ardolino M., Azimi C.S., Iannello A., Trevino T.N., Horan L., Zhang L., Deng W., Ring A. Fischer S., Garcia K.C., Raulet D.H.
Cytokine therapy reverses NK cell anergy in MHC-deficient tumors.
The Journal of Clinical Investigation, 2014, 124 (11):4781-94
3. Ardolino M., Zingoni A., Cerboni C., Cecere F., Soriani A., Iannitto M.L., Santoni A.
DNAM-1 ligands expression on Ag-stimulated T lymphocytes is mediated by ROS-dependent activation of DNA-damage response: relevance for NK-T-cell interaction.
Blood, 2011, 117 (18); 4778-86
All Other Publications
1) Cerboni C., Ardolino M., Santoni A, Zingoni A.
Detuning CD8+ T lymphocytes by
down-regulation of the activating receptor NKG2D: role of NKG2D ligands
released by activated T cells.
Blood, 2009, 113;
2955-64
2) Zingoni A., Cerboni
C., Ardolino M., Santoni A.
Modulation of T-cell mediated immune responses by
Natural Killer cells (Chapter 17).
in J.
Zimmer (Ed): Natural Killer Cells, at the forefront of modern immunology.
Springer, 2010
3) Ardolino M., Zingoni A., Cerboni C.,
Cecere F., Soriani A., Iannitto M.L., Santoni A.
DNAM-1
ligands expression on Ag-stimulated T lymphocytes is mediated by ROS-dependent activation
of DNA-damage response: relevance for NK-T-cell interaction.
Blood, 2011, 117 (18);
4778-86
4)
Zingoni A., Ardolino
M., Santoni S., Cerboni C.
NKG2D
and DNAM-1 activating receptors and their ligands in NK-T cell interactions:
role in the NK cell-mediated negative regulation of T cell responses.
Frontiers in Immunology, 2013, 3; 408
5) Sheppard S.,
Triulzi C., Ardolino M., Serna D.,
Raulet D.H., Guerra N.
Characterization of
a novel NKG2D and NKp46 double-mutant mouse reveals subtle variations in the NK
cell repertoire.
Blood, 2013, 121 (25); 5025-33
6) Iannello A.,
Thompson T.W., Ardolino M., Lowe
S.W., Raulet D.H.
p53-dependent
chemokine production by senescent tumor cells supports NKG2D-dependent tumor
elimination by natural killer cells.
The Journal of Experimental Medicine, 2013, 210 (10); 2057-69
7) Bekerman E., Jeon
D., Ardolino M., Coscoy L.
A role for host
activation-induced cytidine deaminase in innate immune defense against KSHV.
Plos Pathogens, 2013, 9 (11); e1003748
8) Marcus A., Gowen
B.G., Thompson T., Iannello A., Ardolino
M., Deng W., Wang L., Shifrin N., Raulet D.H.
Recognition of
tumors by the innate immune system and natural killer cells.
Advances in Immunology, 2014, 122:91-128
9) Shifrin N., Raulet
D.H., Ardolino M.
NK cell tolerance,
responsiveness and missing self recognition.
Seminars in Immunology, 2014, 26 (2):138-44
10) Ardolino M., Azimi C.S., Iannello A., Trevino
T.N., Horan L., Zhang L., Deng W., Ring A. Fischer S., Garcia K.C., Raulet D.H.
Cytokine
therapy reverses NK cell anergy in MHC-deficient tumors.
The Journal of Clinical Investigation, 2014, 124
(11):4781-94
11) Ardolino M., Hsu J., Raulet D.H.
Cytokine treatment in cancer immunotherapy.
Oncotarget, 2015, 14; 6(23): 1936-7
12) Iannello A., Thompson T.W., Ardolino
M., Marcus A., Raulet D.H.
Immunosurveillance of tumors by innate immune cells.
Current Opinion in
Immunology, 2016, 38: 52-8
13) Ardolino M., Raulet D.H.
Cytokine therapy
restores anti-tumor responses of NK cells rendered anergic in MHC I-deficient
tumors.
Oncoimmunology, 2016, 5(1): e1002725
14) Spiegel A., Houshyar S., Brooks M., Reinhardt F., Ardolino M., Fessler E., DeCock J., Zervantonakis I. K., Ng Eaton
E., Iwamoto Y., Cortez-Retamozo V., Pittet M. K., Raulet D. H., Weinberg
R.A.
Neutrophils
suppress intraluminal NK tumor cell clearance and enhance extravasation.
Cancer Discovery, 2016, 6(6): 630-49
15) Tovbis Shifrin N., Kissov D.U.*, Ardolino
M.*, Joncker N., Raulet D.H.
Differential role of hematopoietic and nonhematopoietic cell types in
the regulation of NK cell tolerance and responsiveness.
The Journal of Immunology, 2016, 197(10):4127-36
* Equal contribution
16) Hsu J.,
Hodgins J.J., Marathe M., Nicolai C.J., Bourgeois-Daigneault M.C., Trevino
T.N., Azimi C.S., Scheer A.K., Randolph H.E., Thompson T.W., Zhang L., Iannello
A., Mathur N., Jardine K.E., Kirn G.A., Bell J.C., McBurney M.W., Raulet D.H. and Ardolino M. Contribution
of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade.
The Journal of Clinical Investigation, 2018, 128(10):4654-4688
PubMed Listings
